Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 1.00 |
| ▸ | SRC | P12931 | 12/20 | 1.00 |
| ▸ | EGFR | P00533 | 9/20 | 1.00 |
| ▸ | WEE1 | P30291 | 3/20 | 0.84 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.84 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.84 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.81 |
| ▸ | ABL1 | P00519 | 8/20 | 0.81 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.81 |
| ▸ | KIT | P10721 | 3/20 | 0.79 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.76 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.76 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.76 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.76 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.76 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.75 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108494 | 0.94 | SRC (0.89) | FGFR1SRCEGFRWEE1FGFR2 | |
| SCHEMBL10108142 | 0.93 | FGFR1 (0.87) | FGFR1SRCEGFRWEE1FGFR2 | |
| SCHEMBL1249524 | 0.91 | FGFR1 (1.00) | FGFR1SRCEGFRWEE1FGFR2 | |
| SCHEMBL5763306 | 0.91 | FGFR1 (1.00) | FGFR1SRCEGFRWEE1FGFR2 | |
| SCHEMBL5764062 | 0.90 | FGFR1 (1.00) | FGFR1SRCEGFRWEE1FGFR2 | |
| SCHEMBL5762046 | 0.89 | SRC (1.00) | FGFR1SRCEGFRWEE1FGFR2 | |
| SCHEMBL1334768 | 0.88 | SRC (1.00) | FGFR1SRCEGFRWEE1FGFR2 | |
| SCHEMBL11939526 | 0.88 | FGFR1 (0.84) | FGFR1SRCEGFRWEE1FGFR2 | |
| SCHEMBL2081574 | 0.88 | SRC (1.00) | FGFR1SRCEGFRWEE1FGFR2 | |
| SCHEMBL2083696 | 0.88 | SRC (1.00) | FGFR1SRCEGFRWEE1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | claimed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | claimed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | claimed |
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | FGFR1 115/4885SRC 176/4885EGFR 48/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | FGFR1 136/4885SRC 194/4885EGFR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.